Quick Answer: Medline (NASDAQ: MDLN) is the largest privately-held-turned-public medical supplies maker in the U.S. After completing a record-breaking $7.2 billion IPO in December 2025 at $29 per share, the stock trades around $37 in mid-2026 — up roughly 28% from its debut. Here's what's driving MDLN, the numbers that matter, and how active traders are positioning around healthcare names.
What Is Medline Inc?
Medline is the largest manufacturer and distributor of medical supplies in the United States — think gloves, gowns, surgical kits, exam tables, and the unglamorous-but-essential consumables that hospitals and clinics burn through every single day. Founded by the Mills family and grown over decades into a healthcare logistics giant, the company sells more than 335,000 products to providers across the globe.
For most of its history, Medline was private. That changed in 2021, when a private equity consortium led by Blackstone, The Carlyle Group, and Hellman & Friedman took it over in a roughly $34 billion leveraged buyout — one of the largest LBOs since the 2008 financial crisis. The exit strategy was always an eventual public listing, and in December 2025 that thesis paid off.
If you're building a watchlist of newly public, high-conviction names, you can track equities and crypto side-by-side in a single account. Create a free Phemex account to start monitoring the markets that matter to you.
The Record-Breaking IPO
On December 18, 2025, Medline priced an upsized IPO of about 248 million Class A shares at $29.00 each, raising approximately $7.2 billion in gross proceeds. The Financial Times called it the largest private-equity-backed IPO of all time — a milestone that put Medline on every institutional trader's radar overnight.
The debut worked. Shares opened above the offer price and have trended higher since, reaching a 52-week high of $50.88 before consolidating into the $37 range by June 2026. That's a healthy return for IPO participants, though the pullback from the highs is a reminder that even quality listings rarely move in a straight line.
The momentum didn't stop at the IPO. In March 2026, selling stockholders — affiliates of Blackstone, Carlyle, Hellman & Friedman, and the Abu Dhabi Investment Authority — launched a secondary offering of 75 million Class A shares, trimming their stakes and adding float to the market.
Medline Stock by the Numbers (Mid-2026)
Here's the snapshot traders are working with:
- Ticker: MDLN (NASDAQ)
- Price: ~$37.13
- 5-Day Move: +6.42% (+$2.24)
- Market Cap: ~$48.78 billion
- P/E Ratio: ~31.1
- 52-Week High / Low: $50.88 / $32.82
- Q1 2026 Revenue: $7.35 billion (+10.66% Y/Y)
- Q1 2026 Earnings: EPS beat by +12.35%, revenue beat by +2.60%
- Dividend: None currently
- Availability on Phemex: Not listed
A P/E above 31 prices MDLN as a growth-flavored healthcare name rather than a sleepy defensive stock. The double-digit revenue growth and the earnings beat support that premium — but it also means the market has expectations baked in, and any miss could compress the multiple quickly.
Want to trade healthcare's biggest names while you wait to see how MDLN matures? [UnitedHealth (UNH) and Eli Lilly (LLY) perpetual contracts are live on Phemex, settled in USDT and tradable 24/7.
⚽ Phemex 2026 Ultimate Championship · $7,000,000 USDT
What's Driving MDLN in 2026?
A few forces are shaping the story:
1. Resilient, recurring demand. Medical consumables aren't discretionary. Hospitals don't stop ordering gloves and sutures during a recession, which gives Medline a defensive revenue base that many high-growth names lack. The +10.66% year-over-year revenue growth shows the demand engine is still accelerating, not just holding steady.
2. Post-IPO float dynamics. With private equity sponsors still holding large positions, the market is watching lockup expirations and secondary offerings closely. The March 2026 secondary added supply; future sales by Blackstone, Carlyle, or Hellman & Friedman could create temporary overhangs that savvy traders anticipate rather than react to.
3. Margin and leverage. Coming out of a $34 billion LBO, Medline carries meaningful debt. As a public company, its ability to pay that down — and its sensitivity to interest rates — will influence how the market values the equity.
4. Healthcare as a macro theme. Aging demographics, expanding global healthcare access, and supply-chain reshoring all play into Medline's long-term tailwinds.
Healthcare is one of the most reliable secular trends in markets. On Phemex, you can build exposure across the whole theme — from MedTech to pharma. Explore the full Phemex stock perpetuals lineup, including NVO, HIMS, and dozens of other USDT-settled equities.
How Traders Are Positioning Around Medline
Here's the key practical point: MDLN is not currently available as a perpetual contract on Phemex. Be cautious of any source claiming you can trade a "MDLNUSDT" pair right now — always verify the ticker on the official markets page before committing capital.
That doesn't mean you're shut out of the trade. Sophisticated traders rarely bet on a single ticker; they express a thesis across correlated names. If your view is "U.S. healthcare and medical supply demand keeps climbing," you can build that exposure today using contracts that are already live:
- UnitedHealth (UNH) — the giant of U.S. health insurance and care delivery.
- Eli Lilly (LLY) and Novo Nordisk (NVO) — pharma leaders riding the GLP-1 boom.
- Hims & Hers (HIMS) — a fast-growing telehealth and consumer-health play.
And there's an elegant indirect angle: Blackstone (BX) — one of Medline's principal private-equity owners — trades as a USDT-settled perpetual on Phemex. When Medline does well, its sponsors benefit, giving BX a loose correlation to the Medline thesis. Trade Blackstone (BX/USDT) and healthcare perpetuals on Phemex with leverage trading, long or short, around the clock.
Trading these as perpetuals carries advantages traditional brokerages can't match: you can go long or short, you trade 24/7 instead of only during market hours, and everything settles in a single USDT account alongside your crypto positions. Phemex was built by former Wall Street engineers for exactly this kind of multi-asset workflow.
Is Medline Stock a Good Investment?
The bull case is straightforward: a market-leading franchise, sticky recurring revenue, double-digit top-line growth, and a clean earnings beat in Q1 2026. The bear case is just as real: a rich ~31x P/E that leaves little room for error, LBO-era debt on the balance sheet, no dividend yet, and ongoing share supply as private equity sponsors continue to exit.
For traders, the takeaway isn't a verdict — it's a framework. Size positions sensibly, respect that a newly public stock can stay volatile, and consider expressing your view through liquid, correlated instruments rather than chasing a single name.
Not Financial Advice (NFA): This article is for informational and educational purposes only and does not constitute investment, financial, or trading advice. Equities and leveraged derivatives are volatile and can result in significant losses. Past performance — including IPO gains — does not guarantee future results. Always do your own research (DYOR) and consult a licensed professional before making any financial decision.
The Bottom Line
Medline's 2026 chapter is one of the most consequential listings in recent market history: a $7.2 billion record IPO, a clean earnings beat, and a stock holding gains well above its debut price. Whether MDLN keeps climbing depends on demand durability, debt reduction, and how gracefully its private-equity backers exit.
You can't trade MDLN on Phemex yet — but you don't have to sit on the sidelines of the healthcare trade. Sign up for Phemex to trade UNH, LLY, NVO, HIMS, Blackstone (BX), and hundreds of other stock and crypto markets — all from one USDT-settled account, 24/7.
